UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
MonumenTAL-3
Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
DREAMM12
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
CAR138 T-Cells
Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- CD138
- Phase 1
Accepting patients
ISB 2001
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
Learn more- T Cell
- BCMA
- CD38
- Phase 1
Accepting patients
ABBV-383
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Phase 1
Accepting patients
Registry of Older Patients With Cancer
Carolina Senior: UNC Registry for Older Cancer Patients
Learn more- Patient Registry
- Observational Trial
Accepting patients
Tissue, Blood, and Body Fluid Sample Collection
Tissue Procurement For Hematolymphoid Conditions
Learn more- Observational Trial
Accepting patients
Isatuximab Combination Therapy
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
Learn more- Immunomodulatory Drug
- Phase 2
Not yet accepting
DISCOVERY
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Learn more- Randomization